Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Liabilities (2023 - 2025)

Historic Total Liabilities for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $20.3 million.

  • BioLineRx's Total Liabilities fell 5417.64% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year decrease of 5417.64%. This contributed to the annual value of $25.4 million for FY2024, which is 4981.46% down from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Total Liabilities is $20.3 million, which was down 5417.64% from $23.2 million recorded in Q2 2025.
  • BioLineRx's 5-year Total Liabilities high stood at $50.7 million for Q4 2023, and its period low was $20.3 million during Q3 2025.
  • For the 3-year period, BioLineRx's Total Liabilities averaged around $34.8 million, with its median value being $37.9 million (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 3361.23% in 2024, then tumbled by 5417.64% in 2025.
  • Over the past 3 years, BioLineRx's Total Liabilities (Quarter) stood at $50.7 million in 2023, then crashed by 49.81% to $25.4 million in 2024, then dropped by 20.33% to $20.3 million in 2025.
  • Its Total Liabilities was $20.3 million in Q3 2025, compared to $23.2 million in Q2 2025 and $22.6 million in Q1 2025.